Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Open Access
- 21 September 2016
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 388 (10057), 2239-2253
- https://doi.org/10.1016/s0140-6736(16)31009-1
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- Large-scale association analysis identifies new risk loci for coronary artery diseaseNature Genetics, 2012
- Inflammation in AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2Free Radical Biology & Medicine, 2011
- Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic MiceJournal of the American College of Cardiology, 2011
- Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary eventsNature Reviews Cardiology, 2009
- A Polymorphism in the Protease-Like Domain of Apolipoprotein(a) Is Associated With Severe Coronary Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Niacin in cardiovascular prevention: mechanisms, efficacy, and safetyCurrent Opinion in Lipidology, 2007
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseThe New England Journal of Medicine, 2006
- The metabolism of apolipoproteins (a) and B-100 within plasma lipoprotein (a) in human beingsMetabolism, 2005
- Receptor-mediated Catabolism of Low Density Lipoprotein in Man. QUANTITATION USING GLUCOSYLATED LOW DENSITY LIPOPROTEINJCI Insight, 1983